Loading
Leads the European LeukemiaNet classification that defines how AML is diagnosed and risk-stratified worldwide.
Hartmut Döhner (Ulm) chairs the European LeukemiaNet AML working group and is first author of the 2010, 2017 and 2022 ELN recommendations that define AML genetic risk groups and response criteria used in every trial and clinic. He leads the German-Austrian AML Study Group, whose trials characterised NPM1, CEBPA and FLT3 mutations as prognostic markers, and co-led the WHO/ELN genomic classification.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia and the tag aml.
Shares FLT3, Acute myeloid leukaemia and the tag aml.
Shares FLT3, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia and the tag guidelines.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.